About us
Bringing a new medicine to market takes more than a decade and billions of dollars. Most are only ever launched in the US, Europe and Japan. By the time their patents expire, up to a third of their value has gone unclaimed.
Our platform lets originators launch in a dozen markets at once, from a single submission.
Services
01
You submit once. Our platform prepares every market's filing from your existing dossier, in parallel.
02
We register the medicine in each territory and become the licence holder.
03
We run the commercial operation on the ground.
04
We are paid out of what the medicine earns. Nothing lands on your team.
Platform
Where our peers build offices, we built software.
One dossier, every filing
The platform reads the dossier your medicine was approved with and assembles each market's submission from it — formats, modules, translations — in parallel rather than one country at a time.
Regulation, encoded
Every territory's requirements, timelines and correspondence live in the system, not in institutional memory. AI drafts; our regulatory team signs.
The long tail, automated
Renewals, variations, safety reporting — the standing work that usually needs a local office — runs through the platform.
Markets
Latin America
Middle East & North Africa
Southeast Asia
The markets where approved medicines arrive late, or never.
Partnering
Who holds the licence?
We do. firstocean becomes the marketing-authorisation holder in each territory and carries everything that entails. The medicine, the brand and the IP stay yours.
What do you need from us?
The dossier you already have, and someone to answer the questions only an originator can. The platform does the rest.
How is firstocean paid?
Out of what the medicine earns in each territory. Our incentive is the same as yours: revenue from markets you would not otherwise enter.
What happens to our core markets?
Nothing. You stay focused on the US, Europe and Japan; we carry the rest.
Contact
Talk to us about your drug.